Skip to main content
. 2024 Jul 1;20(9):3656–3674. doi: 10.7150/ijbs.97091

Table 1.

The correlation between TRIM50 mRNA expression and the patients' clinical pathology data

Characteristic Overall Expression of TRIM50 p
High Low
N 124 62 62
Age, year 64.92 ± 11.70 63.53 ± 12.38 66.31 ± 10.91 0.188
Gender, n (%) 0.208
Female 59 (47.6%) 26 (21.0%) 33 (26.6%)
Male 65 (52.4%) 36 (29.0%) 29 (23.4%)
Tumor volume, cm3 17.86 (13.64, 26.76) 15.75 (13.13, 20.30) 23.65 (14.11, 29.13) 0.002
T classification, n (%) 0.170
I 8 (6.5%) 6 (4.8%) 2 (1.6%)
II 21 (16.9%) 12 (9.7%) 9 (7.3%)
III 40 (32.3%) 22 (17.7%) 18 (14.5%)
IV 55 (44.4%) 22 (17.7%) 33 (26.6%)
N classification, n (%) 0.407
0 25 (20.2%) 16 (12.9%) 9 (7.3%)
1 25 (20.2%) 12 (9.7%) 13 (10.5%)
2 40 (32.3%) 17 (13.7%) 23 (18.5%)
3 34 (27.4%) 17 (13.7%) 17 (13.7%)
M classification, n (%) 0.011
0 116 (93.5%) 62 (50.0%) 54 (43.5%)
1 8* (6.5%) 0 (0%) 8* (6.5%)
Pathologic stage, n (%) 0.011
I 12 (9.7%) 8 (6.5%) 4 (3.2%)
II 40 (32.3%) 24 (19.4%) 16 (12.9%)
III 64 (51.6%) 30 (24.2%) 34 (27.4%)
IV 8* (6.5%) 0 (0%) 8* (6.5%)
OS, month 18.93 (12.02, 34.24) 28.05 (13.38, 36.92) 14.30 (10.42, 32.12) 0.004

“*” denotes patients with resectable single distant metastasis. Bold values indicate an intergroup p <0.05, indicating the presence of a statistically significant difference.